An interventional study of Restrata in Wound Heal, sponsored by Acera Surgical, Inc.. Terminated at 1 site in United States. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2023-04-18.
Sponsored by Acera Surgical, Inc. (part of Solventum) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Understand association between use of Restrata (Acera Surgical Inc., St. Louis, MO) in forearm flap reconstruction with donor site healing and function
Acera Surgical, Inc. is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
First submitted before Acera Surgical, Inc. became part of Solventum.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Restrata
Restrata is a sterile, single use device intended for use in local management of wounds
Tendon Exposure
Percentage of participants with tendon exposure
Time frame: 4 weeks post-operatively
Surface Area of Split-thickness Skin Graft Incorporation
Percentage of surface area of split-thickness skin graft incorporation
Time frame: 4 weeks post-operatively
| Milestone | Restrata With a Split-thickness Skin Graft | Split-thickness Skin Graft Alone |
|---|---|---|
| Started | 3 | 2 |
| Completed | 2 | 2 |
| Not completed | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
Percentage of participants with tendon exposure
| Participants | Restrata With a Split-thickness Skin Graft | Split-thickness Skin Graft Alone |
|---|---|---|
| % of patients with tendon exposure at 4 weeks | 1 | 0 |
| % patients lost to follow up prior to 4 weeks | 1 | 0 |
| % of patients with tendon coverage at 4 weeks | 1 | 2 |
Percentage of surface area of split-thickness skin graft incorporation
| Participants | Restrata With a Split-thickness Skin Graft | Split-thickness Skin Graft Alone |
|---|---|---|
| 90% graft take | 0 | 1 |
| % not assessed due to study termination | 3 | 1 |
Collected over 4 weeks after skin graft harvest. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Restrata With a Split-thickness Skin Graft | 0/3 (0%) | 1/3 (33.3%) | 0/3 (0%) |
| Split-thickness Skin Graft Alone | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) |
| Event | Restrata With a Split-thickness Skin Graft | Split-thickness Skin Graft Alone |
|---|---|---|
| InfectionSkin and subcutaneous tissue disorders | 1/3 | 0/2 |
| Age, Categorical(Participants) | Restrata With a Split-thickness Skin Graft | Split-thickness Skin Graft Alone | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 1 | 2 | 3 |
| >=65 years | 2 | 0 | 2 |
| Age, Continuous(years) | Restrata With a Split-thickness Skin Graft | Split-thickness Skin Graft Alone | Total |
|---|---|---|---|
| Mean | 69.3 ± 4.5 | 49.5 ± 5.5 | 61.4 ± 9.5 |
| Sex: Female, Male(Participants) | Restrata With a Split-thickness Skin Graft | Split-thickness Skin Graft Alone | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 3 | 2 | 5 |
| Ethnicity (NIH/OMB)(Participants) | Restrata With a Split-thickness Skin Graft | Split-thickness Skin Graft Alone | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 3 | 2 | 5 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Restrata With a Split-thickness Skin Graft | Split-thickness Skin Graft Alone | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 3 | 2 | 5 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Restrata With a Split-thickness Skin Graft | Split-thickness Skin Graft Alone | Total |
|---|---|---|---|
| United States | 3 | 2 | 5 |
Ran from Apr 2021 to primary completion in Jan 2022, 8 months.
Results were first posted in Apr 2023, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.